Entinostat + Olaparib
Phase 1TerminatedDevelopment Stage
Fallopian Tube Cancer
Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Oct 1, 2020 → Feb 4, 2022
About Entinostat + Olaparib
Entinostat + Olaparib is a phase 1 stage product being developed by AstraZeneca for Fallopian Tube Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03924245. Target conditions include Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma.
What happened to similar drugs?
0 of 4 similar drugs in Fallopian Tube Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03924245 | Phase 1 | Terminated |
Competing Products
20 competing products in Fallopian Tube Cancer